Therapeutics: Chemokine CX3C motif receptor 1 (CX3CR1)

Mouse studies suggest inhibiting CX3CR1 could help treat the chronic phase of traumatic brain injury (TBI). In a mouse model of chronic-phase TBI, CX3CR1 knockout decreased lesion size, hippocampal damage and the numbers of peripheral macrophages and lymphocytes in the brain one year after injury, and increased fine motor function 80 days after injury, compared with normal CX3CR1 expression. Next steps could include identifying and testing CX3CR1 inhibitors in the model. ...